Adipose Stem Cell Secretome for Spinal Cord Injury Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for traumatic spinal cord injury (SCI) are inadequate, with methylprednisolone showing no conclusive benefits, and there is a need for alternative therapeutic strategies that can effectively promote motor and sensory recovery, axonal regeneration, and reduce inflammatory responses.
Innovation Solution
Administration of a secretome derived from adipose tissue-derived mesenchymal stem cells, which contains neuroregulatory molecules like PEDF, semaphorins, cadherins, IL-6, GDN, clusterin, and β4Gal-T1, administered intravenously or in situ, to modulate the immune response, promote axonal sprouting, and enhance neuronal migration and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylprednisolone is administered for spinal cord injury treatment, then anti-inflammatory effect is achieved, but conclusive beneficial outcomes are not demonstrated and therapeutic efficacy remains insufficient
Solution Approach 1:
The patent extracts and utilizes the secretome fraction from adipose-derived stem cells, separating the therapeutic components (growth factors, cytokines, exosomes) from the whole cell system. This extracted secretome specifically targets inflammatory responses and promotes axonal regeneration without the limitations of methylprednisolone, directly addressing the insufficient therapeutic efficacy while managing inflammation.
Solution Approach 2:
The patent changes the therapeutic parameter from conventional anti-inflammatory drugs to stem cell-derived secretome, which contains a complex mixture of bioactive molecules including growth factors (NGF, BDNF, GDNF), cytokines (IL-6, IL-10, TGF-β), and exosomes. This parameter change provides multi-target action that simultaneously reduces inflammation and promotes regeneration, achieving conclusive beneficial outcomes.
2Adaptability or versatility
If secretome from different stem cell sources is used, then diverse neurotrophic and neurogenic factors are provided, but heterogeneous composition leads to unpredictable therapeutic outcomes
Solution Approach 1:
The patent selects adipose-derived stem cells as the specific source, which have demonstrated superior neuroprotective properties compared to other stem cell sources. The secretome from this specific source provides optimized concentrations of neurotrophic factors (NGF, BDNF, GDNF) and anti-inflammatory cytokines (IL-10, TGF-β), creating a consistent and predictable therapeutic profile while maintaining the diversity of neuroprotective components.
3Ease of operation
If intravenous administration of secretome is performed, then systemic delivery is achieved, but precise localization to injury site may be reduced
Solution Approach 1:
The patent utilizes exosomes present in the secretome as natural delivery vehicles. These exosomes act as intermediaries that carry neurotrophic factors and therapeutic molecules to the injury site through the bloodstream, enabling systemic delivery while achieving precise localization at the spinal cord injury site. The exosomes navigate to the injury location and release their cargo locally, combining the advantages of both intravenous administration and targeted delivery.
Data Source
AI summary
The present disclosure relates to a method and composition for the treatment or therapy of spinal cord injury, the composition comprising a total secretome, obtainable from mesenchymal stem cells. The composition is suitable for systemic delivery, preferably intravenous systemic delivery.